Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 8/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 8/20 | 0.49 |
| ▸ | NQO2 | P16083 | 2/20 | 0.41 |
| ▸ | FERMT2 | Q96AC1 | 2/20 | 0.39 |
| ▸ | CCNC | P24863 | 3/20 | 0.39 |
| ▸ | CDK8 | P49336 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25395839 | 1.00 | HTR1A (0.49) | HTR1AADRA1DADRA1AADRA1BNQO2 | |
| SCHEMBL4819502 | 0.83 | HTR1A (0.44) | HTR1AADRA1DADRA1AADRA1BNQO2 | |
| SCHEMBL28216759 | 0.78 | HTR1A (0.50) | HTR1AADRA1DADRA1AADRA1BNQO2 | |
| SCHEMBL7834381 | 0.76 | CYP1A2 (0.67) | FERMT2 | |
| SCHEMBL25399241 | 0.76 | EGFR (0.44) | HTR1AADRA1DADRA1AADRA1BNQO2 | |
| SCHEMBL25399239 | 0.76 | EGFR (0.44) | HTR1AADRA1DADRA1AADRA1BNQO2 | |
| SCHEMBL30591163 | 0.76 | EGFR (0.44) | HTR1AADRA1DADRA1AADRA1BNQO2 | |
| SCHEMBL6598616 | 0.74 | EGFR (0.63) | HTR1AADRA1DADRA1AADRA1BCCNC | |
| SCHEMBL15472862 | 0.74 | KDM4E (0.62) | HTR1AADRA1DADRA1AADRA1BNQO2 | |
| SCHEMBL25399497 | 0.74 | ALDH1A1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4493562-A1 | TYK2 INHIBITORS AND USES THEREOF | Alumis Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023178235-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178235-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. (US) | 2023-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213571-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | HTR1A 1712/4885ADRA1D 3634/4885ADRA1A 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.